Richard Pearson’s recent article on Cempra $CEMP has most of the details necessary for investors to decide about the stock; except a couple critically medical things. One, comparative safety/efficacy profile of Solithera as seen in the two trials, IV and oral, for CABP (community-acquired bacterial pneumonia). Two, based on that comparison, its chances of success with the NDA. Three, market potential of Solithera, a next-generation macrolide, and a proper valuation of the stock based on that. And lastly, four, other indications and rest of the pipeline. So I will deal with some of these things here.

*** L2 or above subscription required to read the rest of the article ... Login or Subscribe/Upgrade here